Treatment Registry
TR-0485 ActiveRecorded September 2026

Compounded semaglutide

Sold by Coivas · every compounded semaglutide record

The register has not established whether this program ships a vial, a pen, or another form. That is a gap in our record, not a statement about the company.

Price

TermPer monthCharged today
Comparison table, standard monthly

“Semaglutide (monthly) $149 After intro period”

Per month$149Charged today$149
Intro pricing, quarterly (new GLP-1 patients)Introductory

“$ 119 /mo Intro pricing For new GLP-1 users · billed $357 for your first 3 months Save $ 30 with quarterly plan Then renews at $149/mo ($447 every 3 months) unless canceled.”

Per month$119Charged today$357
Standard price after intro, quarterly

“Then renews at $149/mo ($447 every 3 months) unless canceled.”

Per month$149Charged today$447
Price sources
Visit Coivas

We earn nothing from this link. It opens Coivas's website without a paid referral.

History

Fewer than two comparable calendar-month readings are available for a price trend. Day- or week-based supplies, introductory offers and unverified payment terms are not connected in this chart.

  • September 2026 — Entry added to the register

Sourcing and terms

StatesAll 50 states
PrescriberBoth
CancellationCan I cancel at any time? Yes — there are no long-term contracts or cancellation fees. You can pause or cancel your plan at any time from your member portal.

Not yet checked: pharmacy, membership and consult fee.

Recorded from coivas.com. Unlike the price rows above, these carry a summary rather than a word-for-word quotation, so they are not shown in quotation marks.

Notes

  1. 1. September 2026 — All-inclusive pricing (consultation, medication, shipping, support bundled). Home page defaults to showing semaglutide's intro pricing prominently; the exact tirzepatide intro-period figure wasn't printed outside the comparison table (only its standard $229/mo post-intro price is stated in visible text).

Treatment Registry is an independent editorial record. It is not a government registry, a licensing body, or a certification. An entry means we recorded what a company published on a given date. It does not mean we recommend the program, and it does not mean the program is approved by anyone.

This record

Entry
TR-0485
Medication category
compounded semaglutide
Readings
1

Related records

Other records from Coivas

All Coivas programs and terms

Compounded semaglutide at a similar price

The records either side of this one in the recorded spread. Not a ranking, and not a recommendation — a position among 372 records of the same molecule.

Cite this entry

Treatment Registry. (2026). Coivas — compounded semaglutide (TR-0485). Last verified September 2026. Retrieved [your access date], from https://treatmentregistry.com/registry/TR-0485

Replace the bracket with the date you read it. Ours is the date we last checked the figures, which is a different thing and is given separately.